Big plans for the trail? Gear up.
Black Friday in the US and Canada: save up to US$90 or CA$115, respectively, on a new ZOLEO plus four months of prepaid service, with activation included. The route is planned. Your pack is ready. Before you head for the trail, make staying connected part of your preparation. Carry a way to check in when the hike takes you beyond cell coverage. The ZOLEO Satellite Communicator and its companion app let you message loved ones, share your location and send an “I’m OK” check-in beyond cell coverage. Exclusively at zoleo.com.
Savings include activation. Eligible new, never-activated ZOLEO 1500 devices in the US and Canada. Four consecutive months of prepaid service begin at activation. Payment method required; service then continues on the same-tier monthly plan at the then-current rate unless another option is selected. Taxes, add-ons and extra usage are additional. Terms apply.

PSA’s Sunday Sound-Off: November 22nd, 2026
Fuel the Future of Psychedelic Journalism
Want to financially support original, independent reporting like this? You can! Donate at the link below, or just click the advertisement at the top of this article - no purchases or personal information sharing required
The Sunday Rundown
OPINION · Produced in partnership with our friends from Drug Cultures
The Lies, Half-Truths, and Misrepresentations of the Recent 60 Minutes Segment on Kratom
By Skye Hawthorne
Journalist | Host, Drug Cultures
On November 15, 2026, CBS aired an episode of 60 Minutes about kratom as part of a larger report on the American opioid crisis. Framed as an exposé into a legal opioid that can lead to addiction and death, the episode is a one-sided scare job that does not treat the topic with the nuance or journalistic integrity that it deserves.
Kratom, an herbal substance derived from the leaves of a tropical tree in the coffee family, is sold widely throughout the US in the form of powders, extracts, and teas, and contains psychoactive compounds that produce both stimulant-like effects at low doses and opioid-like, sedative effects at high doses. Kratom is also a multi-billion-dollar industry in the United States, and is projected to grow in the coming years (if it remains legal).
There is a real need for hard-hitting journalism that holds the kratom industry to account for deceptive marketing, dishonest product labeling, and secret donations to political PACs, without demonizing a product that millions of people use for many reasons. Yet CBS chose instead to pump out Reefer Madness-style kratom hysteria as opposed to taking an objective look at the industry’s malfeasance or the revolving door-style corruption of the Trump FDA and HHS. In choosing to dismiss or disregard the people who effectively use kratom for pain relief, mental health, or as an opioid replacement, CBS is laying the groundwork for further criminalization that puts users across the country at risk.
The episode opens with a look into the life of Melanie Clark, an opera singer who began using kratom for postpartum depression. In 2022, after seeing ads for the kratom tonic Feel Free, she tried the beverage and became hooked in a matter of weeks. Feel Free bottles contain both kratom and kava, and at the time, the bottles did not say that they contained kratom, nor that kratom could be habit-forming. Only after a class-action lawsuit forced an $8.75 million settlement did the company, Botanic Tonics, add a warning label to its bottles.
The episode does not mention Botanic Tonics’ dishonest advertising, which for any other drug would be the story. Can you imagine a scenario where somebody became an alcoholic because they did not know they were consuming an alcoholic beverage? The episode makes many such misrepresentations. Towards the end of the video, the narrator reports that HHS advisor Calley Means as well as FDA Commissioner Marty Makary both told 60 Minutes they recently resigned from their posts in part because of changes to kratom policy shaped by business interests instead of public health. And it is certainly true that the kratom industry has spent millions to lobby the Trump Administration; Botanic Tonics donated $1 million to MAHA PAC, a political action committee aligned with HHS Secretary RFK Jr., for example. HHS, which declined an interview, said in a statement to 60 Minutes that neither political contributions nor outside pressure influenced its recommendation. But Means’ and Makary’s problems with the Trump Administration’s health-related decisions go far beyond kratom policy. Makary, for example, felt pressure from the White House to legalize flavored vapes, which he disagreed with. And for Means, his biggest problems were what he saw as a series of betrayals to the MAHA (Make America Healthy Again) agenda, including Trump’s decision to increase production of the pesticide glyphosate and the tabling of healthy school lunch initiatives.
CBS had the opportunity to present this story in the broader context of a corrupt administration. But alas, connecting those dots might be a bridge too far for a network whose new leadership has gone out of its way to accommodate the Trump White House.
Much of the episode focuses on a panel of parents whose (adult) children died with mitragynine — the most prominent kratom alkaloid — in their system. They had purchased kratom products in stores or online and believed they were taking a safe substance. All the parents, to some extent, blame kratom or kratom products for the tragic deaths of their sons and daughters. But there’s a question CBS fails to ask, and uncomfortable though it may be, it’s something journalists must always ask when reporting on kratom deaths: did these people die because of kratom, or did they happen to have kratom in their systems at the time of death?
Most opioid overdose deaths are caused through respiratory depression; opioids inhibit the neurons responsible for controlling the diaphragm and other muscles required for breathing. Kratom alkaloids, particularly at concentrations found in unadulterated leaf kratom, have not been shown to trigger respiratory depression. This fact is borne out in many of the autopsies of kratom-associated deaths; for all the talk of kratom as a dangerous opioid, very few of the alleged kratom deaths bear any resemblance to opioid overdoses.
For one of the mothers featured in the 60 Minutes episode, her son allegedly died of a kratom-induced seizure and subsequent cardiac arrest. This is not the typical symptom profile of an opioid overdose, and while there is some evidence to indicate that mitragynine can increase the risk of seizure in otherwise healthy individuals, a direct causal link has not been established. Among the mothers featured in the episode is the anti-kratom activist and documentarian Patti Wheeler, whose son had a seizure in 2022. According to the medical examiner’s report, his death was due to the “combined toxic effects of mitragynine, doxylamine, hydroxyzine, and sertraline.” DPH (the active ingredient in Benadryl), amphetamine, DXM and marijuana metabolites were also found in his system.
The last thing I want to do is attack or misrepresent the words of a grieving parent or the death of her child. But deaths attributed to kratom have been used to advance legislation that bans kratom in cities, counties, and states across the country — bans that may also lead to the death of people who rely on the plant to stay clean from other drugs. In July 2026, a bill called Matthew Davenport’s Law went into effect that banned kratom statewide in Tennessee. Named after a man who died in 2024 of a purported kratom overdose, the toxicology report tells a now-familiar story: elevated levels of mitragynine, yes, but also 3,000 ng/mL of DPH (enough to cause a fatal overdose all by itself) as well as high levels of multiple prescription anti-anxiety and antidepressant medications.
Not what you're looking to read? We get it!
Pick the PSA Content you want to see by updating your preferences at the link below
The episode goes on to feature an interview with Dr. Andrew Kolodny, who asserts that “the effects produced by kratom are very similar to the effects produced by oxycodone, heroin, even fentanyl.”
This claim is not true for the vast majority of kratom users. Opioids like heroin and fentanyl, especially at higher doses, frequently cause a “nodding off” effect of extreme sedation and partial consciousness. The effect can be pleasurable, of course, but also extremely dangerous, and the line between a pleasurable experience and a lethal overdose is razor-thin, particularly with fentanyl and its highly potent analogues, which are often present in street opioids at unknown quantities. Roughly 780,000 Americans used illicit fentanyl in 2025, with around 38,000 fentanyl deaths — a staggering 5% fatality rate.
While it may be possible for some kratom users to experience the opioid nod, the vast majority do not; many, in fact, use the plant for its stimulating properties, a statement rarely heard about drugs like fentanyl (though sometimes asserted about weaker opioids like tramadol). More importantly, the risk of a lethal overdose is demonstrably lower for kratom than for fentanyl by orders of magnitude. A recent study in the Journal of Addiction Medicine found that over 5 million Americans have used kratom in their lifetimes, and a 2021 study found that over a million Americans had used it in the past year. In spite of these numbers, the CDC figures used in the 60 Minutes report show kratom’s involvement in less than 1,000 overdose deaths annually, with the vast majority involving other substances.
When asked whether kratom might help the 10 million Americans struggling with opioid addiction, Dr. Kolodny was unequivocal: “Don’t use kratom,” he said. “When it comes to kratom for opioid use disorder, we don’t have the evidence. And what is available suggests that the risks of kratom outweigh the potential benefits.”
Kolodny has long advocated for a different kind of opioid replacement therapy: buprenorphine, more commonly known by its brand name Suboxone. Buprenorphine essentially acts as a safer opioid for addicts and, similar to kratom, activates opioid receptors without triggering dangerous respiratory depression. Still, buprenorphine can be extremely habit-forming and difficult to quit, and has been implicated in a handful of overdose deaths, usually alongside other substances. In 2018, Kolodny testified before Congress that buprenorphine should be easier for doctors to prescribe. “If we want more patients to seek treatment, it needs to cost less than a bag of heroin,” he declared. “Until that happens, I believe opioid overdose deaths will remain at historically high levels.”
In spite of the parallels between buprenorphine and kratom (which is also cheaper than a bag of heroin), Kolodny takes diametrically opposing perspectives, and dismisses the idea of kratom for opioid replacement as an industry talking point. Yet the NIH is already exploring mitragynine as a treatment for opioid use disorder, and just this year, the FDA cleared its Investigational New Drug application, allowing research into the therapeutic potential of the kratom alkaloid to proceed.
The most glaring error committed by CBS in its 60 Minutes segment on kratom was its complete lack of an attempt to represent the other side of the kratom debate.
The American Kratom Association (AKA) was given only passing mention in the 13-minute video despite being the largest kratom lobbying group and consumer advocacy organization in the world. In a tweet released the same day as the 60 Minutes video, the AKA stated that they were contacted by the producers for an on-camera interview, but had this interview cancelled multiple times. The AKA provided CBS with the names of 60+ kratom advocates, none of whom were interviewed on camera for the story. The AKA has since issued a demand for CBS to correct what it calls “major errors” in the 60 Minutes reporting.
Certainly, no lobbying group is above criticism. I have been very critical of the AKA, and have reported on the industry’s aggressive lobbying of the Trump administration myself. But this episode was aired as part of a broader series on the opioid crisis. And the fact that no kratom users or advocates were interviewed for the story, or that none of those interviews were aired, is borderline journalistic malpractice, particularly considering that many of them use kratom to stay off other, more dangerous opioids.
And the problem goes beyond the lack of advocates; none of the scientists who have studied kratom’s effects for decades (such as Dr. Kirsten Smith or Dr. Chris McCurdy) were given airtime either.
As I mentioned at the top, we need real journalism that holds the kratom industry to account. We need product transparency, particularly from any business selling extract products or chemically manipulated kratom-derived alkaloids like 7-OH or MGPI. But reporting must be fair, evidence-based, and include the voices of all groups who will be affected by policy changes, including kratom users who have been fighting for legal access to this plant for years.
Editorial Disclosure: Drug Cultures is a PSA media partner. The views expressed are the author’s own and do not necessarily reflect those of Psychedelic State(s) of America.
Related PSA Coverage
PSA EVENT
Editorial Disclosure: PSA founder Jack Gorsline also founded The Psychedelic Writers Guild. Lucid News is a PSA media partner. Global Psychedelic Week is a PSA media partner.
ICYMI: The State(s) of Psychedelic Storytelling at the Shulgin Farm
Highlights from The Psychedelic Writers Guild’s evening at the home and lab of Ann and Sasha Shulgin
On November 5, during Global Psychedelic Week, The Psychedelic Writers Guild gathered at the Shulgin Farm in Lafayette, California — where Ann and Sasha Shulgin lived and worked — for “The State(s) of Psychedelic Storytelling: Past, Present, and Future.”
Annie Oak Harrison of Lucid News, Mareesa Stertz and filmmaker Lindsay Kent joined moderator Jack Gorsline to talk about keeping the writing human instead of outsourcing it to AI, reporting difficult experiences alongside the good ones, and remembering that most psychedelic use happens outside the clinic. The three-minute recap also takes you through the house and lab where the Shulgins did their work.
Photos and tour footage by Lindsay Kent.
Support The Psychedelic Writers Guild
The Guild is building a higher standard of credibility, ethics and quality in psychedelic journalism and media — one writer, filmmaker and podcaster at a time. Help it grow.
Elevate. Amplify. Inform. #BuildTheGuild
PSA NewsWire Highlights of the Week
November 22, 2026

This Week's Highlights
📜 Law & Policy

Over at The Kathmandu Post
By Amrit Baral
💰 Business

Over at PharmaVoice
By Meagan Parrish
🎨 Culture

From our friends at DoubleBlind
By Mary Carreón
Editorial Disclosure: DoubleBlind is a PSA media partner.
💊 Science & Research

Over at New Scientist
By Caroline Williams
Enjoyed this Sunday Sound‑Off? Subscribe to Psychedelic State(s) of America and share this post with someone who should read it.
More from PSA: PsychedelicAmericas.Org
Until next time,
The Psychedelic State(s) of America Team
Psychedelic State(s) of America is committed to fostering rigorously diverse debate and discourse on all psychedelics-related topics.
While PSA publishes a broad range of commentary and opinion pieces as part of our broader content offerings, that does not mean that PSA team members agree with every perspective published on our site.
We welcome feedback and input on our editorial process, as well as submissions for consideration to be featured in PSA's Sunday Sound‑Off series. To pitch an op-ed, use our Sunday Sound‑Off submission form.
For feedback and more information, contact PSA Founder Jack Gorsline at [email protected] 24/7/365.



